Tamura et al. examined how HER2 and HER3 mutations conveyed sensitivity to the targeted therapies dacomitinib (PIK3CA) and afatinib, an irreversible HER family inhibitor, in bladder cancer via in vitro methods [46]. Here, PIK3CA is linked to urinary bladder cancer.